Objective. To study the characteristics of asthenic syndrome and the potential for treating it in the postcovid period. Materials and methods. A continuous sampling method was used to select 129 patients (mean age 49.8 ± 8.9 years) after COVID-19. Study patients were selected at the clinical out-patient and polyclinic facilities in Samara in the period July–August, 2020. All patients signed informed consent. The envelope method was used to randomize patients into two groups: the study group (n = 64) received ethylmethylhydroxypyridine succinate (Neurox) 1 tablet (125 mg) three times daily for four weeks; medications in the reference group (n = 65) did not include any substances of the pharmacological antihypoxant/antioxidant/nootrope groups. Three visits (V) were made: the first (V1) was before inclusion in the study; the second (V2) was at 14 days; the third (V3) was on day 28 from treatment initiation. The dynamics of overall status (weakness, fatigue, concentration of attention, vertigo, headache, sleep impairment) were evaluated on a visual analog scale (VAS); the subjective perception of the severity of asthenia (tiredness, physical and mental fatigue, decreased motivation and activity) was evaluated using the Multidimensional Fatigue Inventory, MFI-20); cognitive functions were assessed using the Mini Mental State Examination (MMSA); and autonomic tone was assessed using the Kérdö index. Results. At the end of the study (V3), statistically significant changes in measures (VAS, MFI-20) were seen only in patients of the study group; the Kérdö Index showed no statistically significant differences. Analysis of MMSE data revealed a decline in cognitive functions in both groups, which may be linked with pseudocognitive deficit due to asthenia. Conclusions. Our studies yielded evidence of a high incidence of asthenic syndrome after COVID-19. Neurox decreased the severity and extent of the symptoms of asthenia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
World Health Organization, Coronavirus Disease 2019 (COVID-19): Situation Report-55, WHO, Geneva (2020).
H. Hozhabri, F. S. Sparascio, H. Sohrabi, et al., “The global emergency of novel coronavirus (SARS-CoV-2): An update of the current status and forecasting,” Int. J. Environ. Res. Public Health, 17, No. 16, 5648 (2010), https://doi.org/10.3390/ijerph17165648.
Y. Yang, F. Peng, R. Wang, et al., “The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China,” J. Autoimmun., 109, 102434 (2020).
R. Talotta and E. Robertson, “Autoimmunity as the comet tail of COVID-19 pandemic,” World J. Clin. Cases, 8, No. 17, 3621–3644 (2020), publ. online Sept. 6 2020, https://doi.org/10.12998/wjcc.v8.i17.3621.
C. Li and L. L. Wang, “Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection,” Virus Res., 286, 198073 (2020), https://doi.org/10.1016/j.virusres.2020.198073.
L. Zheng, L. Zhang, J. Huang, et al., “Potential treatment methods targeting 2019-nCoV infection,” Eur. J. Med. Chem., 205, 112687 (2020), https://doi.org/10.1016/j.ejmech.2020.112687.
J. G. Rizk, K. Kalantar-Zadeh, M. R. Mehra, et al., “Pharmaco-immunomodulatory therapy in COVID-19,” Drugs, 80, No. 13, 1267–1292 (2020), https://doi.org/10.1007/s40265-020-01367-z.
N. C. Abbot, “Chronic fatigue syndrome,” Lancet, 67, No. 9522, 1574 (2006).
O. V. Kotova and E. S. Akarachkova, “Asthenic syndrome in the practice of a neurologist and a family doctor practice,” Ross. Med. Zh., 13, 824–829 (2016).
G. M. Dyukova, “Asthenic syndrome: problems of diagnosis and therapy,” Eff. Nevrol. Psikhiatr., No. 1, 16–22 (2012).
I. E. Poverennova, I. A. Zolotovskaia, and E. V. Bezgina, “Diagnosis and treatment of asthenic syndrome in elderly people with acute respiratory viral infections,” Zh. Nevrol. Psikhiatr., 114, No. 9, 73–76 (2014).
O. A. Shavlovskaya, “Therapy of asthenic conditions in patients after stroke,” Farmateka, 19, 56–61 (2013).
A. N. Zinchuk, E. A. Zubach, A. Ya. Orfin, and O. Yu. Plevachuk, “Asthenic syndrome and its correction in patients with infectious pathology,” Semeinaya Med., No. 4, (84), 41–46 (2019).
N. A. Maslennikova, E. P. Tikhonova, and L. A. Mikhailova, “Clinical aspects of hepatic echinococcosis,” Sovrem. Prob. Nauki Obraz., 5, 22 (2018).
Yu. D. Vorob’eva and G. M. Dyukova, “Asthenic syndrome in the context of the COVID-19 pandemic,” Meditsinsk. Alfavit, 33, 26–34 (2020).
M. G. Zhestikova, M. Yu. Gerasimenko, S. L. Kan, et al., “Management of COVID-19 patients with asthenic syndrome,” Vrach, 31, 29–32 (2020).
M. Pennisi, G. Lanza, L. Falzone, et al., “SARS-CoV-2 and the nervous system: from clinical features to molecular mechanisms,” Int. J. Mol. Sci., 21, No. 15, 5475 (2020).
E. Brown, R. Gray, S. Lo Monaco, et al., “The potential impact of COVID-19 on psychosis: a rapid review of contemporary epidemic and pandemic research,” Schizophr. Res., 222, 79–87 (2020).
J. M. Trejo-Gabriel-Galán, “Stroke as a complication and prognostic factor of COVID-19,” Neurología, 35, No. 5, 318–322 (2020).
P. Mehta, D. F. McAuley, M. Brown, et al., “COVID-19: consider cytokine storm syndromes and immunosuppression,” Lancet, 395, No. 10229, 1033–1034 (2020).
K. Bohmwald, N. M. S. Gálvez, M. Ríos, and A. M. Kalergis, “Neurologic alterations due to respiratory virus infections,” Front. Cell. Neurosci., 12, 386 (2018).
E. M. Smets, B. J. Garssen, B. Bonke, and J. C. DeHaes, “The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue,” J. Psychosom. Res., 39, 315–325 (1995), https://doi.org/https://doi.org/10.1016/0022-3999(94)00125-O.
I. Kérdö, ”Ein aus Daten der Blutzirkulation kalkulierter Index zur Beurteilung der vegetativen Tonuslage, Acta Neurovegetativa, 29, No. 2, 250–268 (1966).
M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-mental state: A practical method for grading the cognitive state of patients for the clinician,” J. Psychiatr. Res., 12, No. 3, 189–198
I. S. Preobrazhenskaya, “Mild and moderate cognitive disorders – clinical manifestations, etiology, pathogenesis, and the potential of nootropic therapy,” Farmateka, 4–13, 14–18 (2013).
A. Tsatsakis, D. Calina, L. Falzone, et al., “SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19,” J. Food Chem. Toxicol., 146, 111769 (2020), publ. online Sept. 30, 2020, https://doi.org/https://doi.org/10.1016/j.fct.2020.111769.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 4, Iss. 1, pp. 25–30, April, 2021.
Rights and permissions
About this article
Cite this article
Zolotovskaia, I.A., Shatskaia, P.R., Davydkin, I.L. et al. Postcovid-19 Asthenic Syndrome. Neurosci Behav Physi 52, 191–195 (2022). https://doi.org/10.1007/s11055-022-01222-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-022-01222-6